回顾ASCO2016:乳腺癌领域3大亮点解读

2016-06-17 潇潇 医学界肿瘤频道

ASCO大会三阴性乳腺癌及乳腺外科领域的热点体会。

在2016年6月3号~7号召开的ASCO年会上,由复旦大学附属肿瘤医院邵志敏教授团队主持的 CBCSG010临床试验入围本次ASCO的壁报讨论环节。

昨天,记者采访了刚从ASCO大会归来的复旦大学附属肿瘤医院乳腺外科的李俊杰医生,李医生给我们介绍了这项研究的细节,并分享了他对此次ASCO大会三阴性乳腺癌及乳腺外科领域的热点体会。

TNBC辅助化疗新选择:纳入卡培他滨或将改善患者无复发生存

三阴性乳腺癌(TNBC)是指免疫组化标记ER、PR、Her-2均为阴性的乳腺癌,占所有乳腺癌的10%~15%,多发于年轻女性,由于没有有效的靶点,治疗手段有限,辅助治疗主要依靠化疗。目前标准的辅助化疗方案为含蒽环及紫衫类的药物。

由复旦大学附属肿瘤医院邵志敏教授团队主持的CBCSG010临床试验是一项针对TNBC患者辅助化疗方案的大规模III期临床研究。该研究一共纳入了全国35家中心,筛选了636例早期三阴性乳腺癌术后患者,在标准蒽环及紫衫方案基础上加用卡培他滨的新方案(3周期卡培他滨联合多西紫杉醇方案序贯3周期环磷酰胺、表阿霉素和卡培他滨)较标准方案(3周期多西紫杉醇方案序贯3周期环磷酰胺、表阿霉素、氟尿嘧啶方案)相比,其安全性及耐受性均较好,随访30个月的结果显示联合卡培他滨能降低43%的复发风险(HR为0.57)。

李俊杰医生向我们介绍道,CBCSG-10研究是目前在Clinical Trial数据库中查询到的国际唯一一个正在进行的验证卡培他滨在TNBC辅助化疗疗效的临床试验。TNBC患者术后2~3年是一个复发高峰,此次中位随访时间为30个月,已经显示联合卡培他滨治疗组能改善患者无复发生存率。但这仍然是一个早期探索性分析结果,最终的5年随访结果大约会在2018年6月份出炉。让我们一起期待最终的研究结果。

谈到今年ASCO大会上TNBC领域的其他看点,李医生表示,大会中有不少关于TNBC有效靶点和免疫治疗这些方面的探索,但都尚在临床试验阶段,对肿瘤科医生而言,目前的临床实践重点在优化化疗方案上,而紫杉联合蒽环的化疗方案仍旧是一个经典。

初诊Ⅳ期乳腺癌患者,首选全身治疗还是手术治疗?

对于初诊为Ⅳ期的转移性乳腺癌,原发病灶有没有必要进行手术干预?首选全身治疗还是手术治疗?在这个问题上,美国的TBCRC013研究结果和土耳其的MF07-01研究结果互相冲突,引发热点讨论和争议。

美国的TBCRC 013 是一项多中心前瞻性研究,主要评价 IV 期的乳腺癌患者原发灶手术治疗对生存期的影响。研究发现,无论属于乳腺癌哪种分型(ER/HER2),对化疗有反应者接受手术治疗与不接受手术相比,其生存期均无明显改变,也就是说手术治疗在全身治疗获益的情况下可能并不能提高晚期乳腺癌患者的预后。

而土耳其MF07-01研究结果刚好相反:手术处理原发灶之后再进行系统治疗与单纯系统治疗相比,前者的中位生存期更长,研究组认为对IV 期乳腺癌患者先进行原发灶手术干预的效果较好。

如何解释这两个截然相反的研究结果呢?李俊杰医生表示,先手术再全身治疗的做法能够减轻肿瘤负荷、减少耐药株的出现,可能有一定的临床意义,然而目前在肿瘤医院,普遍的晚期乳腺癌治疗方案是全身治疗为主、外科为辅的治疗原则,需要根据患者对全身治疗的反应情况评估后续的治疗方案,一味先手术治疗不可取,而原发灶手术干预的时机还需要个体化的探讨。

1-2枚前哨淋巴结阳性的保乳患者不需行腋窝淋巴结清扫

在此前,著名的ACOSOG Z0011研究结果已经显示,对于肿瘤分期为T1-2 N0 M0且术中活检发现有1-2枚前哨淋巴结阳性的乳腺癌保乳患者,如不接受淋巴结清扫,仅行乳腺放疗和辅助性系统性治疗,其总生存期(OS)和无疾病生存期(DFS)并不比接受腋窝淋巴结清扫(ALND)的患者差。

此次ASCO大会上,洛杉矶西奈医疗中心的 Giuliano 团队进一步分析了 ACOSOG Z0011 乳腺癌患者的 10 年生存情况,结果与早期试验结果一致,即肿瘤分期为T1-2 N0 M0且伴有1-2枚前哨淋巴结(SN)阳性患者接受ALND的生存结果并不优于不清扫的患者。

李俊杰医生表示,目前1-2枚前哨淋巴结阳性的乳腺癌患者不进行补充淋巴结清扫已经成为肿瘤医院的常规处理原则,这一结果的公布更加确证了该原则的可靠性,将对临床有指导意义。
乳腺癌相关的拓展阅读:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780045, encodeId=c7d71e8004591, content=<a href='/topic/show?id=c91c28348a' target=_blank style='color:#2F92EE;'>#ASCO2016#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2834, encryptionId=c91c28348a, topicName=ASCO2016)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Dec 28 21:08:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938597, encodeId=2c06193859ee7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 24 14:08:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90408, encodeId=d96c9040840, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:13:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90258, encodeId=c41590258a3, content=女人的天敌, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b711667381, createdName=JBY, createdTime=Fri Jun 17 22:35:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90233, encodeId=d8569023344, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160614/IMG57601F0AE0AE82959.jpg, createdBy=f7d91683038, createdName=Jallylable, createdTime=Fri Jun 17 15:37:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90231, encodeId=1845902317a, content=不知道没什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Jun 17 14:56:00 CST 2016, time=2016-06-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1780045, encodeId=c7d71e8004591, content=<a href='/topic/show?id=c91c28348a' target=_blank style='color:#2F92EE;'>#ASCO2016#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2834, encryptionId=c91c28348a, topicName=ASCO2016)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Dec 28 21:08:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938597, encodeId=2c06193859ee7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 24 14:08:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90408, encodeId=d96c9040840, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:13:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90258, encodeId=c41590258a3, content=女人的天敌, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b711667381, createdName=JBY, createdTime=Fri Jun 17 22:35:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90233, encodeId=d8569023344, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160614/IMG57601F0AE0AE82959.jpg, createdBy=f7d91683038, createdName=Jallylable, createdTime=Fri Jun 17 15:37:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90231, encodeId=1845902317a, content=不知道没什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Jun 17 14:56:00 CST 2016, time=2016-06-17, status=1, ipAttribution=)]
    2017-02-24 quxin068
  3. [GetPortalCommentsPageByObjectIdResponse(id=1780045, encodeId=c7d71e8004591, content=<a href='/topic/show?id=c91c28348a' target=_blank style='color:#2F92EE;'>#ASCO2016#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2834, encryptionId=c91c28348a, topicName=ASCO2016)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Dec 28 21:08:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938597, encodeId=2c06193859ee7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 24 14:08:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90408, encodeId=d96c9040840, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:13:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90258, encodeId=c41590258a3, content=女人的天敌, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b711667381, createdName=JBY, createdTime=Fri Jun 17 22:35:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90233, encodeId=d8569023344, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160614/IMG57601F0AE0AE82959.jpg, createdBy=f7d91683038, createdName=Jallylable, createdTime=Fri Jun 17 15:37:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90231, encodeId=1845902317a, content=不知道没什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Jun 17 14:56:00 CST 2016, time=2016-06-17, status=1, ipAttribution=)]
    2016-06-18 沉心多思

    好文章,值得学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1780045, encodeId=c7d71e8004591, content=<a href='/topic/show?id=c91c28348a' target=_blank style='color:#2F92EE;'>#ASCO2016#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2834, encryptionId=c91c28348a, topicName=ASCO2016)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Dec 28 21:08:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938597, encodeId=2c06193859ee7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 24 14:08:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90408, encodeId=d96c9040840, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:13:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90258, encodeId=c41590258a3, content=女人的天敌, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b711667381, createdName=JBY, createdTime=Fri Jun 17 22:35:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90233, encodeId=d8569023344, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160614/IMG57601F0AE0AE82959.jpg, createdBy=f7d91683038, createdName=Jallylable, createdTime=Fri Jun 17 15:37:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90231, encodeId=1845902317a, content=不知道没什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Jun 17 14:56:00 CST 2016, time=2016-06-17, status=1, ipAttribution=)]
    2016-06-17 JBY

    女人的天敌

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1780045, encodeId=c7d71e8004591, content=<a href='/topic/show?id=c91c28348a' target=_blank style='color:#2F92EE;'>#ASCO2016#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2834, encryptionId=c91c28348a, topicName=ASCO2016)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Dec 28 21:08:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938597, encodeId=2c06193859ee7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 24 14:08:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90408, encodeId=d96c9040840, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:13:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90258, encodeId=c41590258a3, content=女人的天敌, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b711667381, createdName=JBY, createdTime=Fri Jun 17 22:35:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90233, encodeId=d8569023344, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160614/IMG57601F0AE0AE82959.jpg, createdBy=f7d91683038, createdName=Jallylable, createdTime=Fri Jun 17 15:37:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90231, encodeId=1845902317a, content=不知道没什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Jun 17 14:56:00 CST 2016, time=2016-06-17, status=1, ipAttribution=)]
    2016-06-17 Jallylable

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1780045, encodeId=c7d71e8004591, content=<a href='/topic/show?id=c91c28348a' target=_blank style='color:#2F92EE;'>#ASCO2016#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2834, encryptionId=c91c28348a, topicName=ASCO2016)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bcaa382, createdName=fzwish20000, createdTime=Wed Dec 28 21:08:00 CST 2016, time=2016-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938597, encodeId=2c06193859ee7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Fri Feb 24 14:08:00 CST 2017, time=2017-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90408, encodeId=d96c9040840, content=好文章,值得学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=53751677671, createdName=沉心多思, createdTime=Sat Jun 18 18:13:00 CST 2016, time=2016-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90258, encodeId=c41590258a3, content=女人的天敌, beContent=null, objectType=article, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1b711667381, createdName=JBY, createdTime=Fri Jun 17 22:35:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90233, encodeId=d8569023344, content=赞, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160614/IMG57601F0AE0AE82959.jpg, createdBy=f7d91683038, createdName=Jallylable, createdTime=Fri Jun 17 15:37:00 CST 2016, time=2016-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=90231, encodeId=1845902317a, content=不知道没什么, beContent=null, objectType=article, channel=null, level=null, likeNumber=103, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2018/12/07/86eb8ff0cc5e04d9b292a27c2970a0be.jpg, createdBy=73691616008, createdName=text, createdTime=Fri Jun 17 14:56:00 CST 2016, time=2016-06-17, status=1, ipAttribution=)]
    2016-06-17 text

    不知道没什么

    0

相关资讯

ASCO 2016:CDK4/CDK6抑制剂Abemaciclib转移性乳腺癌II期临床试验积极结果(MONARCH 1试验)

2016年美国临床肿瘤协会年会(ASCO)召开,制药巨头礼来在会议上公布了CDK4/CDK6抑制剂abemaciclib在HR+/HER2-转移性乳腺癌中的II期临床试验结果。该项名为MONARCH 1的临床试验数据由纪念斯隆凯特琳癌症中心的Maura Dickler口头汇报展示。 MONARCH1是一项单臂临床研究,纳入了132名此前接受过一到两种化疗以及激素治疗方案并发生疾病进展的HR+/H

乳腺癌和卵巢癌竟然遗传自父亲

英国一位女士Alison Dagul被诊断为侵略性的乳腺癌和卵巢癌,经过血液测试后发现病因是基因缺陷。她不仅从父亲那里继承了这种基因缺陷,而且检测结果表明这种基因缺陷还遗传给了自己的女儿——24岁的Gaby。父亲携带基因突变 致女儿患癌Alison表示:“在得知癌症诊断结果的几个星期前,我还是一个健康的50岁妇女。我曾看着自己的儿女长大成人,并期待着与我的丈夫安东尼共度美好的晚年。但是突然间,

ASCO 2016:奥拉帕利(Olaparib)全面开战:卵巢癌、乳腺癌、胃癌

Abstract 5501  Study19研究:Olaparib治疗BRCA突变铂敏感复发的浆液性卵巢癌的总生存期(OS)数据更新报道 Oral Abstract Session 背景: II期研究Study19显示,olaparib维持治疗对比安慰剂,可以显著延长铂敏感复发的高级别浆液性卵巢癌患者的无进展生存期(PFS),其中BRCA1/2基因突变(BRCAm)的患者接受ola

Nature 子刊:浸润性乳腺癌治疗前景

在瑞士有超过5700名妇女被诊断为乳腺癌,每年几乎有1400名患者死于该病。许多入侵形式的乳腺癌中的癌细胞表面有很多HER2受体,这将导致癌细胞不受控制的生长发展。有很多种抗体如曲妥珠单抗和帕妥珠单抗可以识别HER2受体,这在乳腺癌治疗中已经使用许多年了。然而,这些抗体不能杀死癌细胞。相反,癌细胞可以使它们处于休眠状态,这样癌细胞在任何时间里都可以自由生长复制。 为什么抗体治疗对乳腺癌细胞无

Cell Res:新研究表明预防乳腺癌有戏

大约8名女性中就有一人将在她的一生当中患上浸润性乳腺癌。这可能是使用人工合成性激素和其他环境因子导致的,也可能是BRCA1基因等发生突变导致的。平均而言,BRCA1基因发生突变的女性有高达87%的风险患上乳腺癌。截至目前,预防性手术切除是显著降低乳腺癌风险的唯一方法,但是这也经常伴随着术后并发症。2010年,奥地利科学院分子生物技术研究所(IMBA)科学主任Josef Penninger和他的

NEJM:延长芳香抑制剂辅助治疗乳腺癌10年效果怎样?

在激素受体阳性的早期乳腺癌的绝经后女性患者中,用芳香酶抑制剂前期单一治疗5年或在他莫昔芬治疗后治疗是首选的治疗方法。用芳香酶抑制剂延长10年治疗可进一步减少乳腺癌复发的风险。原始出处:Paul E. Goss,James N. Ingle,Kathleen I. Pritchard,et al.Extending Aromatase-Inhibitor Adjuvant Therapy to 10